Effects of polybrene and retronectin as transduction enhancers on the development and phenotypic characteristics of VHH-based CD19-redirected CAR T cells: a comparative investigation

Identification of a small molecule for enhancing lentiviral transduction of T cells

“…No impact on RT kinetics or lentiviral integration profile was identified in this study. Several studies have demonstrated the applicability of previously described TEs to other cell and vector types, 10 , 14 , 17 , 18 , 19 , 20 , 21 , 22 , 23 suggesting some commonalities in their mechanisms of action. It would be of interest to conduct further studies to determine whether GSK2622391 is also able to enhance transduction in other cell or vector types.…”

“…Several TEs have been shown to work synergistically. 17 While much of the focus has been on TEs for lentiviral transduction of HSCs, their use has also been reported in other cell types, including T cells, 14 , 18 , 19 , 20 , 21 mesenchymal stem cells (MSCs), 10 , 22 and dendritic cells, 23 and with other types of vectors including adenovirus 23 and α-retrovirus. 17 …”

“…Although polybrene has been widely used because of its low cost, ease of use, and efficacy in many cell types, it is also toxic to cells at higher concentrations and has been shown to alter cellular characteristics, including differentiation and proliferation of MSCs 22 and T cells. 18 RetroNectin resulted in a change in the proportion of T cell memory subtypes, 18 PGE2 reduced CD90 + long-term repopulating HSCs, 17 and rapamycin reduced cell-cycle progression and proliferation in HSCs. 16 Not all the TEs described are compatible with good manufacturing practice (GMP).…”

Biosynthesis cobalt‐doped nickel nanoparticles and their toxicity against disease

“…As a common worldwide disease that is caused by various factors including lifestyle, genetic (Li et al, 2021; Nasiri, Kazemi, et al, 2022), and so forth (Sargazi et al, 2022), the approach of nanomaterials application is one of the emerging strategies for its treatment with the ability to increase the rate of drugs transfer to cancer cells (Al‐Ouqaili et al, 2023), which would consequently facilitate an effective drug delivery and control over the side effects (Barani et al, 2022; Barani, Khatami, et al, 2023). In addition, this method can extend the therapeutic impacts and suppression of side effects in non‐cancerous cells (Amiri et al, 2016; Nasiri et al, 2023; Nasiri, Muhammadnejad, et al, 2022).…”